Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANGO NASDAQ:ANIK NASDAQ:ATRS NASDAQ:XENT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGOAngioDynamics$9.32-1.7%$9.87$5.82▼$13.50$384.95M0.6582,901 shs388,725 shsANIKAnika Therapeutics$11.27-4.3%$11.57$10.47▼$29.12$168.94M0.6476,030 shs76,049 shsATRSAntares Pharma$5.59$5.59$3.11▼$5.60$955.06M1.153.29 million shs6 shsXENTIntersect ENT$28.24$28.24$15.92▼$28.25$954.91M1.45351,526 shs14,512 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGOAngioDynamics-1.69%-2.82%-14.50%+0.32%+66.43%ANIKAnika Therapeutics-4.33%+0.04%-0.35%-17.38%-56.98%ATRSAntares Pharma0.00%0.00%0.00%0.00%0.00%XENTIntersect ENT0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANGOAngioDynamics3.9508 of 5 stars3.52.00.04.21.61.70.6ANIKAnika Therapeutics4.3232 of 5 stars3.83.00.03.72.71.70.6ATRSAntares Pharma1.885 of 5 stars0.00.00.03.60.60.83.1XENTIntersect ENTN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGOAngioDynamics 3.00Buy$14.0050.21% UpsideANIKAnika Therapeutics 3.50Strong Buy$20.0077.46% UpsideATRSAntares Pharma 0.00N/AN/AN/AXENTIntersect ENT 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANGO, XENT, ANIK, and ATRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ANIKAnika TherapeuticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.004/17/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/16/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGOAngioDynamics$303.91M1.25$4.22 per share2.21$5.13 per share1.82ANIKAnika Therapeutics$119.91M1.35$0.09 per share123.50$10.51 per share1.07ATRSAntares Pharma$183.98M5.19$0.13 per share43.89$1.03 per share5.43XENTIntersect ENT$106.75M8.95N/AN/A($2.06) per share-13.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGOAngioDynamics-$184.35M-$1.01N/AN/AN/A-14.61%-3.73%-2.43%7/15/2025 (Estimated)ANIKAnika Therapeutics-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)ATRSAntares Pharma$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/AXENTIntersect ENT-$159.63M-$4.79N/AN/AN/A-161.94%-709.52%-48.18%N/ALatest ANGO, XENT, ANIK, and ATRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/15/2025Q4 2025ANGOAngioDynamics-$0.13N/AN/AN/A$74.26 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGOAngioDynamicsN/AN/AN/AN/AN/AANIKAnika TherapeuticsN/AN/AN/AN/AN/AATRSAntares PharmaN/AN/AN/AN/AN/AXENTIntersect ENTN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGOAngioDynamicsN/A2.211.40ANIKAnika TherapeuticsN/A5.734.53ATRSAntares Pharma0.103.082.87XENTIntersect ENT6.891.881.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGOAngioDynamics89.43%ANIKAnika Therapeutics91.53%ATRSAntares Pharma50.41%XENTIntersect ENT92.47%Insider OwnershipCompanyInsider OwnershipANGOAngioDynamics5.40%ANIKAnika Therapeutics9.64%ATRSAntares Pharma5.90%XENTIntersect ENT2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANGOAngioDynamics76040.61 million38.41 millionOptionableANIKAnika Therapeutics30014.34 million12.96 millionOptionableATRSAntares Pharma201170.85 million160.77 millionOptionableXENTIntersect ENT43333.81 million33.10 millionOptionableANGO, XENT, ANIK, and ATRS HeadlinesRecent News About These CompaniesZee Ent. - Zee Entertainment Enterprises Share PriceAugust 2, 2024 | economictimes.indiatimes.comKiatnakin Bank PCL (KKP)July 26, 2024 | investing.comAt the Intersection of Law & PolicyMarch 1, 2024 | slu.eduS74-year-old woman killed in east Charlotte crash, CMPD saysDecember 6, 2023 | wsoctv.comWWhat 4 Execs Want People To Know About the Intersection Between the Justice System and Behavioral HealthNovember 29, 2023 | medcitynews.comMTraffic signal installed at notorious Riverside intersection where crash killed 8-year-oldNovember 4, 2023 | nbclosangeles.comNRogue Robotaxi Tries To Drive Down Footpath, Reverses Into IntersectionOctober 30, 2023 | jalopnik.comJXENT Historical DataOctober 21, 2023 | investing.comVideo shows Brightline train goes through intersection while bars up; officials explain whyOctober 5, 2023 | tcpalm.comTIntersection Into Proposed Cricket Stadium OK'd By Kendall BoardSeptember 26, 2023 | patch.comMusic At The Intersection Festival Tells St. Louis’ Rich Musical HistorySeptember 12, 2023 | yahoo.com4-way stop coming to Poinciana intersection where crash killed 4September 12, 2023 | clickorlando.comCWeaver intersection to finally open, Plainview close as extension work continuesSeptember 9, 2023 | news-leader.comNMore social space, less traffic noise: The award-winning reno on a busy intersectionSeptember 2, 2023 | smh.com.auCode of conduct prepared for peace, intersect harmony during Muharram: AyazAugust 31, 2023 | radio.gov.pkREuclid looking to increase safety at intersection following studyAugust 28, 2023 | news-herald.comNCruise car reportedly swerves in backhoe's way, is busted in SF intersectionAugust 28, 2023 | sfgate.comToronto is about to get a new type of intersection unlike any it's seen beforeAugust 27, 2023 | blogto.comBWatch: US Woman Points Gun At Cars On Intersection, Cop Drives Cruiser Into HerAugust 19, 2023 | ndtv.comNLawsuit claims Iowa City teens were 'drag racing' when they struck Jennifer Russell's car in an intersectionJuly 19, 2023 | press-citizen.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?ANGO, XENT, ANIK, and ATRS Company DescriptionsAngioDynamics NASDAQ:ANGO$9.32 -0.16 (-1.69%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$9.86 +0.54 (+5.78%) As of 07/11/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.Anika Therapeutics NASDAQ:ANIK$11.27 -0.51 (-4.33%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$11.30 +0.04 (+0.31%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Antares Pharma NASDAQ:ATRSAntares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.Intersect ENT NASDAQ:XENTIntersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
